Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Chemical modification or the reaction product thereof – e.g.,...
Reexamination Certificate
2005-02-01
2005-02-01
Horlick, Kenneth R. (Department: 1637)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Chemical modification or the reaction product thereof, e.g.,...
C435S069100, C435S183000, C514S04400A, C536S023100
Reexamination Certificate
active
06849721
ABSTRACT:
A 2.4 Å crystal structure of a protein construct containing the catalytic kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2/KDR), a key enzyme in angiogenesis, has been determined in an unliganded, phosphorylated state. This protein construct, contains a modified catalytic linker and has comparable in vitro kinase activity to constructs containing the entire KID. The resulting construct retains comparable in vitro kinase activity to that of the wild-type KID, and more importantly, allows complete crystallization of the protein such that it may be characterized by X-ray crystallography. The present invention further discloses the use of the x-ray crystallographic data for identification and construction of possible therapeutic compounds in the treatment of various disease conditions.
REFERENCES:
patent: 4966849 (1990-10-01), Valee et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 20020164641 (2002-11-01), McTigue et al.
patent: 20040059091 (2004-03-01), Ohta et al.
patent: WO9115495 (1991-10-01), None
patent: WO9220642 (1992-11-01), None
patent: WO9221660 (1992-12-01), None
patent: WO9403427 (1994-02-01), None
patent: WO9410202 (1994-05-01), None
patent: WO9849300 (1998-11-01), None
Adamis et al.,Arch. Ophthalmol., 114:66-71 (1996).
Agouron Pharmaceuticals, Inc. “Agouron Solves Structure of Key Target for Drugs to Block Angiogenesis: Human VEGF Receptor 2 Kinase”, Mar. 4, 1999.
Bazenet et al.,Mol. Cell. Biol., 16:6926-6936 (1996).
Borgström et al,Cancer Res., 56:4032-4039 (1996).
Bourne, H.R., et al.,Basic&Clinical Pharmacology, 3rdEdition(Katzung et al., eds), Chapter 3, pp. 9-22 (1987).
Choudhury et al.,FEBS Letters, 282(2):351-354 (May, 1991).
Dvorak et al.,Am. J. Path., 146:1029-1039 (1995).
DeVries et al.,Science, 255:989-991 (1992).
Dougher-Vermazen et al.,Biochem. Biophys. Res. Comm., 205:728-738 (1994).
Ferrara & Henzel,Biochem. Biophys. Res. Comm, 161:851-858 (1989)—Abstract Only.
Ferrara N. and Davis-Smyth,Endocrine Rev., 18:4-25 (1997).
Folkham,J. Natl., Cancer Inst., 82:4-6 (1991).
Folkman et al.,J. Biol. Chem., 267:10931-10934 (1992).
Heidaran et al.,Mol. Cell. Biol., 11:134-142 (1991).
Hori et al.,Cancer Res., 51:6180-9184 (1991).
Houck, et al.,J. Biol. Chem., 267:26031-26037 (1992).
Hubbard,EMBO J., 16:5572-5581 (FGFR1) (1997).
Hubbard, et al.,Nature, 372:746-754 (1994).
Jellinek, et al.,Biochemistry, 3:10450-56 (1994).
Johnson et al.,Cell, 85:149-158 (1996).
Kazlauskas et al.,Mol. Cell. Biol., 12:2534-2544 (1992).
Kim et al.,Nature, 362:841-843 (1993).
Kinsella, et al.,Exp. Cell Res., 199:56-62 (1992).
Klagsburn & Soker,Current Biology, 3:699-702 (1993).
Knighton et al.,Science, 253:407-413 (1991).
Kumar and Fidler,In Vivo, 18:27-34 (1998)—Abstract only.
Lev et al.,Proc. Natl. Acad. Sci. USA, 89:678-682 (1992).
Matsui,T., et al.,Science, 243:800-804 (1989).
McLeskey et al.,Cancer Res., 53:2168-2177 (1993).
McRee et al.,J. Struct. Biol., 125(2-3):156-165 (1999)—Abstract only.
Mohammadi et al.,Cell, 86:577-87 (1996).
Mohammadi et al.,Science, 276:955-960 (1997).
Mullis, et al.Biotechnology, 24:17-27 (1992)—Abstract Only.
Parast et al.,Biochemistry, 37(47):16788-16801 (Nov. 5, 1998).
Pepper, M.S.,Vasc. Med., 1:259-266 (1996)—Abstract Only.
Reedjik, et al.,EMBO J., 11:1365-1372 (1992).
Risau, W.,FASEB J., 9:926-933 (1995).
Schuchter, et al.,Cancer Res., 51:682-687 (1991).
Seetharm, et al.,Oncogene, 10:135-147 (1995).
Severinsson et al.,Mol. Cell. Biol., 10:801-809 (1990).
Shalaby et al.,Nature, 376:576-579 (1995).
Shibuya, et al.,Oncogene, 5:519-524 (1990).
Szekanecz, et al.,J. Investig. Med., 46:27-41 (1998).
Takano, et al.,Mol. Bio. Cell, 4:358A, (1993).
Taylor, et al.,EMBO Journal, 8(7):2029-2037 (1989).
Terman et al.,Biochem Biophys. Res. Commun., 187:1579-8 (1992).
Thomas, K.,J. Biol Chem, 271(2):603-606 (1996)—Abstract only.
Thomas & Kendall,Proc. Natl. Acad. Sci., 90:10705-09, (1994).
Tolentino and Adamis,Int. Ophthalmol. Clin. 38:77-94 (1988).
Vaisman et al.,J. Biol. Chem., 265:19461-19566, (1990).
van der Geer et al.,Ann. Rev. Cell Biol, 10:251-337, (1994)—Abstract only.
Waltenberger et al.,J. Biol. Chem., 269:26988-26995, (1994).
Wei et al.,J. Biol. Chem., 270:8122-8130, (1995).
Weidner, et al.,New Engl. J. Med., 324:1-5, (1991).
Yamaguchi and Hendrickson,Nature, 384:484-489 (1996).
Yu et al.,Mol. Cell. Biol., 11:3780-3785 (1991).
McTigue, et al. “Crystal Structure of the Kinase Domain of Human Vascular Endothelial Growth Factor Receptor 2: A Key Enzyme in Angiogenesis,” Structure 1999; 7:319-330.
Al-Obeidi, et al., “Protein Tyrosine Kinases: Structure, Substrate Specificity, and Drug Discovery,” Biopolymers (Peptide Science), vol. 47, 197-223 (1998).
Wei, et al., “Expression, Characterization, and Crystallization of the Catalytic Core of the Human Insulin Receptor Protein-tyrosine Kinase Domain,” J. Biol. Chem. 1995; 270(14):8122-8130.
Hubbard, et al., “Crystal Structure of the Tyrosine Kinase Domain of the Human Insulin Receptor,” Nature 1994;372:746-759.
SCOPES, “Protein Purification: Principles and Practice,” Second Ed., 1987, pp. 297-301.
Mohammadi, et al., “Structure of the Tyrosine Kinase Domain of Fibroblast Growth Receptor in Complex with Inhibitors,” Science 997; 276: 955-960.
McDonald, et al., “The First Structure of a Receptor Tyrosine Kinase Domain: A Further Step in Understanding the Molecular Basis of Insulin Action,” Structure 1995; 3:1-6.
Singh, et al., Structure-Based Design of a Potent, Selective, and Irreversible Inhibitor of the Catalytic Domain of the erbB Receptor Subfamily of Protein Tyrosine Kinases, J. Med. Chem. 1997; 40: 1130-1135.
McTigue, et al., “Crystal Structure Of The Kinase Domain Of Human Vascular Endothelial Growth Factor Receptor 2: A Key Enzyme In Angiogenesis,”Structure(1999) vol. 7, No. 3, pp. 319-330.
Appelt Krzysztof
Gehring Michael R.
Kan Chen-Chen
McTigue Michele A.
Mroczkowski Barbara
Agouron Pharmaceuticals , Inc.
Desai Reena R.
Horlick Kenneth R.
Kim Young J.
Richardson Peter C.
LandOfFree
Modifications of the VEGF receptor-2 protein and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modifications of the VEGF receptor-2 protein and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modifications of the VEGF receptor-2 protein and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3512653